On January 3, 2025, Snehal Patel, CEO and CFO, 10% Owner of Greenwich LifeSciences Inc (GLSI, Financial), purchased 3,400 shares of the company. Following this transaction, the insider now holds a total of 5,547,102 shares. The purchase was documented in a SEC Filing.
Greenwich LifeSciences Inc is a biopharmaceutical company focused on the development of immunotherapy products for the treatment of cancer. The company's lead product candidate, GP2, is designed to prevent the recurrence of breast cancer following surgery.
The recent insider purchase by Snehal Patel is part of a broader trend within the company. Over the past year, the insider has acquired a total of 264,925 shares and has not sold any shares. This activity aligns with the overall insider transaction history for Greenwich LifeSciences Inc, which shows 21 insider buys and no insider sells over the past year.
Shares of Greenwich LifeSciences Inc were trading at $12.95 each on the day of the purchase, resulting in a market cap of $172.326 million for the company.
This insider buying activity may be of interest to investors who track insider trends as a potential indicator of a company's future performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
